Amarna Therapeutics Receives Constructive Feedback from FDA INTERACT Meeting for AM510 Gene Therapy Development Targeting Type 1 Diabetes Amarna Therapeutics Receives Constructive Feedback from FDA INTERACT Meeting for AM510 Gene Therapy Development Targeting Type 1 Diabetes Leiden, The Netherlands, 27th August 2024 - Amarna...

PROCESSA PHARMACEUTICALS TO MOVE FORWARD WITH A PCS499 PHASE 3 TRIAL AFTER A SUCCESSFUL FDA MEETING HANOVER, MD, March 30, 2020 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (OTCQB: PCSA), announced the successful completion of their meeting with the U.S. Food and Drug Administration (FDA)...